Nuvectis Pharma (NVCT) Enterprise Value (2021 - 2026)
Nuvectis Pharma has reported Enterprise Value over the past 6 years, most recently at -$25.1 million for Q1 2026.
- Quarterly results put Enterprise Value at -$25.1 million for Q1 2026, up 16.05% from a year ago — trailing twelve months through Mar 2026 was -$25.1 million (up 16.05% YoY), and the annual figure for FY2025 was -$31.6 million, changed.
- Enterprise Value reached -$25.1 million in Q1 2026 per NVCT's latest filing, up from -$31.6 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$13.6 million in Q2 2022 and bottomed at -$35.4 million in Q3 2025.
- Median Enterprise Value over the past 5 years was -$22.9 million (2022), compared with a mean of -$22.8 million.
- The largest annual shift saw Enterprise Value rose 26.36% in 2024 before it plummeted 106.43% in 2025.
- Over 5 years, Enterprise Value stood at -$23.6 million in 2022, then grew by 6.51% to -$22.1 million in 2023, then rose by 22.31% to -$17.2 million in 2024, then crashed by 84.25% to -$31.6 million in 2025, then increased by 20.65% to -$25.1 million in 2026.
- Business Quant data shows Enterprise Value for NVCT at -$25.1 million in Q1 2026, -$31.6 million in Q4 2025, and -$35.4 million in Q3 2025.